Nelly Munikah v. BioReference Laboratories, Inc.

CourtDistrict Court, D. New Jersey
DecidedJanuary 28, 2026
Docket2:22-cv-05570
StatusUnknown

This text of Nelly Munikah v. BioReference Laboratories, Inc. (Nelly Munikah v. BioReference Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nelly Munikah v. BioReference Laboratories, Inc., (D.N.J. 2026).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

NELLY MUNIKAH, Civil Action No. 22-5570 Plaintiff,

v. OPINION

BIOREFERENCE LABORATORIES, INC., January 28, 2026

Defendant.

SEMPER, District Judge. THIS MATTER comes before the Court on Defendant BioReference Laboratories, Inc.’s (“Defendant” or “BioReference”) motion for summary judgment. (ECF 59, “Mot.”) Plaintiff Nelly Munikah filed an opposition to Defendant’s motion. (ECF 64, “Opp.”) The Court reviewed the submissions made in support of and in opposition to the motion and decided the motion without oral argument pursuant to Federal Rule of Civil Procedure 78 and Local Civil Rule 78.1. For the reasons stated below, Defendant’s motion for summary judgment is GRANTED. I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY1 This lawsuit arises from Plaintiff’s allegations of a hostile work environment and retaliation following her termination from her employer. Plaintiff Nelly Munikah was employed

1 The facts and procedural history are drawn from Defendant’s brief in support of the motion for summary judgment (ECF 59-1), Defendant’s statement of undisputed material facts (ECF 59-2, “DSMF”), Plaintiff’s opposition papers containing a statement of facts (ECF 64), and Plaintiff’s response to Defendant’s statement of material facts (ECF 64, Exhibit P, “Pl. Response.”). Plaintiff withdrew her statement of material facts, which falsely claimed that Defendant did not produce documents in discovery and quoted unproduced emails in the submission. (ECF 76,) by Defendant BioReference as a cytotechnologist for ten years. (Opp. at 7, 11.) Plaintiff, a black woman, was hired in 2010 and worked in Defendant’s New Jersey lab, and in 2013 she was transferred to Defendant’s Florida location. (Id.; DSMF ¶ 2.) As a cytotechnologist, Plaintiff examined specimens for the presence of abnormal cellular changes and pathogens, which in

practice constituted reviewing and diagnosing slides with cell samples. (DSMF ¶ 3.) Plaintiff “saw herself as an efficient screener, and she was typically able to review the maximum number of slides permitted per day.” (Id. ¶ 4.) Cytotechnologists employed by BioReference are non- exempt hourly employees subject to a Recording Work Hours Policy (the “Policy”) that “strictly” prohibits off-the-clock work and requires employees to record their time worked accurately. (Id. ¶¶ 7-8.) The Policy “clearly states that those who do not accurately record their time are subject to discipline, up to and including termination.” (Id. ¶ 8.) At Defendant’s Florida lab, Plaintiff reported to the supervisor of Cytology Operations, Christopher Schouest. (Id. ¶ 2.) In 2014, Schouest complemented Plaintiff’s work and gave her additional quality control duties, which involved reviewing diagnoses made by her peers. (Id. ¶ 9;

Opp. at 8.) In 2017, after Hurricane Irma hit Florida, Plaintiff began working weekends and taking Mondays and Tuesdays off, even though her supervisor continued to work regular weekdays. (DSMF ¶¶ 10, 11.) That same year, Schouest removed Plaintiff’s quality control duties for several weeks because of issues with her diagnoses. (Id. ¶ 12.) Plaintiff believed that Schouest temporarily removed these duties because she had corrected slides reviewed by another cytotechnologist, Penny Uzzetta, who Plaintiff believed Schouest “favored” over the others. (Id. ¶¶ 14, 15.) Plaintiff also believed that Schouest and Uzzetta were “romantically involved because they seemed close[.]” (Id. ¶ 15.) At Plaintiff’s request, the lab Pathologist, Dr. Cote, reviewed her slides and “disagreed and agreed with some of Munikah’s calls[.]” (Id. ¶ 13; Opp. at 8.) Schouest then returned Plaintiff’s quality control duties. (Opp. at 8.) On June 29, 2018, Schouest issued Plaintiff a written warning for working unscheduled and unapproved overtime hours. (DSMF ¶ 17.) The warning stated that Plaintiff “failed to clock

out at the 8 mark of scheduled shift 7 of 9 days worked this pay period after 2 previous email request[s] to keep an eye on clock out time.” (ECF 59-6, “Ex. A”.) The warning called for corrective action, specifying that Plaintiff “will not work unscheduled shifts (weekend shifts) and timecard will be monitored daily until this has been resolved.” (Id.) During this period, Schouest observed that Plaintiff was diagnosing low-grade squamous intraepithelial lesion (“LSIL”) at a rate “well above” the laboratory average. (DSMF ¶ 21.) On August 10, 2018, he brought these “abnormal submissions” to Plaintiff’s attention and provided her with examples to show that her diagnostic methods were not “in line” with her colleagues’ work. (Id. ¶ 22.) On September 2, 2018, after Plaintiff continued to work overtime without permission, Schouest issued another written warning. (Id. ¶ 18.)

Ten days later, on September 12, 2018, Schouest met with Plaintiff and Human Resources (“HR”) partner Leah Browne to place Plaintiff on a performance improvement plan (“PIP”) because her LSIL diagnosis rate had increased in the month of August, after the issue had already been brought to her attention. (Id. ¶ 23.) After being placed on the PIP, Plaintiff met with Browne to complain that the PIP was unfair, and that Schouest was targeting her unfairly due to favoritism of other cytotechnologists like Uzzetta. (Id. ¶ 29.) Plaintiff told Browne that she “would gather evidence to prove she should not have been placed on the PIP.” (Opp. at 10.) Plaintiff then manually went through all the slides she reviewed for quality control over the past three months to disprove the necessity of the PIP, which entailed “extensive unauthorized off-the-clock-hours” of work. (DSMF ¶ 32.) Plaintiff did not seek permission for these additional hours, nor did Schouest or Browne authorize her to do so. (Id. ¶ 33.) On September 21, 2018, Schouest noticed on Plaintiff’s daily work reports that she was spending “considerable time compiling information regarding whether the pathologist agreed with her diagnoses, so he checked to ensure Munikah

had signed out slides for review,” and noticed that she had signed out slides “hours after she clocked out.” (Id. ¶ 35.) Schouest discovered that Plaintiff has worked a total of 70 unauthorized, off-the-clock hours in 2018. (ECF 59-6, “Ex. J”.) That same day, Schouest reached out to BioReference management to report Plaintiff’s off-the-clock work and suggested that Plaintiff move back to her pre-2017 Monday through Friday work shift to help combat the issue. (DSMF ¶ 36.) BioReference’s Executive Vice President and Laboratory Director Dr. James Weisberger, who was based in New Jersey, instructed that Plaintiff should be terminated and “noted another employee was terminated for similar issues.” (Id. ¶ 37.) Five days later, on September 26, 2018, Browne and Schouest met with Plaintiff to explain that BioReference was terminating her employment because of her off-the-clock work, and they

explained that the decision came from management in New Jersey. (Id. ¶ 38.) Defendant terminated Plaintiff rather than give her a warning “because of the egregiousness of her violation.” (Id. ¶ 42.) Following her termination, Plaintiff sent two grievance letters to Defendant. (Id. ¶ 43.) In her first letter dated October 4, 2018, Plaintiff wrote that her grievances include “Discrimination, Harassment, and Retaliatory Treatment; Inequitable, Prejudiced, and Weaponized Allegations of ‘Unauthorized’ Work Hours; and the Blatant Misrepresentation, Omission, and Falsification of Facts” which “were made known to HR weeks prior to my being terminated” by Defendant. (ECF 59-4, “Ex.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Nelly Munikah v. BioReference Laboratories, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/nelly-munikah-v-bioreference-laboratories-inc-njd-2026.